Christian Iorio-Morin1, Rosalie Mercure-Cyr1, Gabrielle Figueiredo2, Charles Jean Touchette1, Laurence Masson-Côté3, David Mathieu4. 1. Division of Neurosurgery, Department of Surgery, Université de Sherbrooke, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, 3001, 12e avenue Nord, Sherbrooke, QC, J1H 5N4, Canada. 2. Department of Radiology, Université de Sherbrooke, Sherbrooke, QC, Canada. 3. Department of Radiation Oncology, Université de Sherbrooke, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada. 4. Division of Neurosurgery, Department of Surgery, Université de Sherbrooke, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, 3001, 12e avenue Nord, Sherbrooke, QC, J1H 5N4, Canada. david.mathieu@usherbrooke.ca.
Abstract
PURPOSE: Stereotactic radiosurgery (SRS) is a well-established treatment option for brain metastases (BM). Repeat SRS for progressive BM is an increasingly used paradigm, although little data is available to support this practice. The goal of this study was to assess the safety and efficacy of a second SRS procedure on a previously treated BM. METHODS: We performed a retrospective metastasis-level analysis of patients who underwent two SRS procedures on the same lesion and for whom at least 6 months of radiological follow-up was available. The data collected included patient characteristics, clinical symptoms at time of treatment, SRS parameters, radiological response per RANO-BM criteria, clinical evolution and survival. RESULTS: Seventy-five BM in 56 patients were included in the analysis. Most frequent primary histologies were non-small-cell lung cancer (59%) and breast cancer (19%). At the second SRS, median treatment volume was 1.19 cc (range 0.07-20.6) treated with a median margin dose of 18 Gy (range 12-20) at the 50% isodose line (range 30-80%). Median follow-up was 11 months. Progression per RANO-BM criteria occurred in 31%, yielding actuarial local control at 1, 2, and 5 years of 68%, 54% and 54% respectively. At last follow-up, 10 patients (18%) had improved relative to the initial presentation, while 21 (38%) were stable and 25 (44%) were deteriorated. Radiation-induced edema and radionecrosis occurred in 8.3% and 5% respectively. The median survival from the diagnosis of BM was 30 months. CONCLUSION: Repeat SRS is a safe and effective novel therapeutic approach to consider in carefully selected patients.
PURPOSE: Stereotactic radiosurgery (SRS) is a well-established treatment option for brain metastases (BM). Repeat SRS for progressive BM is an increasingly used paradigm, although little data is available to support this practice. The goal of this study was to assess the safety and efficacy of a second SRS procedure on a previously treated BM. METHODS: We performed a retrospective metastasis-level analysis of patients who underwent two SRS procedures on the same lesion and for whom at least 6 months of radiological follow-up was available. The data collected included patient characteristics, clinical symptoms at time of treatment, SRS parameters, radiological response per RANO-BM criteria, clinical evolution and survival. RESULTS: Seventy-five BM in 56 patients were included in the analysis. Most frequent primary histologies were non-small-cell lung cancer (59%) and breast cancer (19%). At the second SRS, median treatment volume was 1.19 cc (range 0.07-20.6) treated with a median margin dose of 18 Gy (range 12-20) at the 50% isodose line (range 30-80%). Median follow-up was 11 months. Progression per RANO-BM criteria occurred in 31%, yielding actuarial local control at 1, 2, and 5 years of 68%, 54% and 54% respectively. At last follow-up, 10 patients (18%) had improved relative to the initial presentation, while 21 (38%) were stable and 25 (44%) were deteriorated. Radiation-induced edema and radionecrosis occurred in 8.3% and 5% respectively. The median survival from the diagnosis of BM was 30 months. CONCLUSION: Repeat SRS is a safe and effective novel therapeutic approach to consider in carefully selected patients.
Entities:
Keywords:
Brain metastases; Local recurrence; Repeat treatment; Stereotactic radiosurgery
Authors: Paul D Brown; Kurt Jaeckle; Karla V Ballman; Elana Farace; Jane H Cerhan; S Keith Anderson; Xiomara W Carrero; Fred G Barker; Richard Deming; Stuart H Burri; Cynthia Ménard; Caroline Chung; Volker W Stieber; Bruce E Pollock; Evanthia Galanis; Jan C Buckner; Anthony L Asher Journal: JAMA Date: 2016-07-26 Impact factor: 56.272
Authors: John T Lucas; Hentry G Colmer; Lance White; Nora Fitzgerald; Scott Isom; John D Bourland; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-23 Impact factor: 7.038
Authors: David W Andrews; Charles B Scott; Paul W Sperduto; Adam E Flanders; Laurie E Gaspar; Michael C Schell; Maria Werner-Wasik; William Demas; Janice Ryu; Jean-Paul Bahary; Luis Souhami; Marvin Rotman; Minesh P Mehta; Walter J Curran Journal: Lancet Date: 2004-05-22 Impact factor: 79.321
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316
Authors: Christian Iorio-Morin; Roman Liscak; Vilibald Vladyka; Hideyuki Kano; Rachel C Jacobs; L Dade Lunsford; Or Cohen-Inbar; Jason Sheehan; Reem Emad; Khalid Abdel Karim; Amr El-Shehaby; Wael A Reda; Cheng-Chia Lee; Fu-Yuan Pai; Amparo Wolf; Douglas Kondziolka; Inga Grills; Kuei C Lee; David Mathieu Journal: Neurosurgery Date: 2019-10-01 Impact factor: 4.654
Authors: Timothy D Solberg; James M Balter; Stanley H Benedict; Benedick A Fraass; Brian Kavanagh; Curtis Miyamoto; Todd Pawlicki; Louis Potters; Yoshiya Yamada Journal: Pract Radiat Oncol Date: 2011-09-15
Authors: Isabela Peña Pino; Jun Ma; Yusuke S Hori; Elena Fomchenko; Kathryn Dusenbery; Margaret Reynolds; Christopher Wilke; Jianling Yuan; Ethan Srinivasan; Matthew Grabowski; Peter Fecci; Evidio Domingo-Musibay; Naomi Fujioka; Gene H Barnett; Veronica Chang; Alireza M Mohammadi; Clark C Chen Journal: J Neurooncol Date: 2022-01-10 Impact factor: 4.130
Authors: Kyle C Wu; Jonathan M Cantalino; Edward C Dee; Liangge Hsu; Thomas C Harris; Bhupendra Rawal; Parikshit R Juvekar; Michael A Mooney; Ian F Dunn; Ayal A Aizer; Phillip M Devlin; Wenya Linda Bi Journal: Neurooncol Adv Date: 2022-04-22
Authors: Xuguang Chen; Vishwa S Parekh; Luke Peng; Michael D Chan; Kristin J Redmond; Michael Soike; Emory McTyre; Doris Lin; Michael A Jacobs; Lawrence R Kleinberg Journal: Neurooncol Adv Date: 2021-10-25
Authors: Nadine Heßler; Stephanie T Jünger; Anna-Katharina Meissner; Martin Kocher; Roland Goldbrunner; Stefan Grau Journal: BMC Cancer Date: 2022-03-15 Impact factor: 4.430
Authors: Brandon S Imber; Robert J Young; Kathryn Beal; Anne S Reiner; Alexandra M Giantini-Larsen; Simone Krebs; Jonathan T Yang; David Aramburu-Nunez; Gil'ad N Cohen; Cameron Brennan; Viviane Tabar; Nelson S Moss Journal: J Neurooncol Date: 2022-07-27 Impact factor: 4.506